MedTrace Logo MedTrace
Clinical Trials News Drugs Diseases Companies About

Relatlimab

  1. Home
  2. Drugs
  3. Relatlimab
  4. Clinical Trials

Clinical Trials Related to Relatlimab

Related studies linked through entity extraction aliases.

NCT02996110

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Status
COMPLETED
Phase
PHASE2

NCT02966548

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Status
COMPLETED
Phase
PHASE1

NCT02935634

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Status
COMPLETED
Phase
PHASE2

NCT02750514

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Status
TERMINATED
Phase
PHASE2

NCT02519322

Neoadjuvant and Adjuvant Checkpoint Blockade

Status
COMPLETED
Phase
PHASE2

NCT02488759

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

Status
COMPLETED
Phase
PHASE1/PHASE2

NCT02465060

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status
ACTIVE_NOT_RECRUITING
Phase
PHASE2

NCT01968109

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Status
COMPLETED
Phase
PHASE1/PHASE2
Previous

Next

Clinical Trials

Explore studies by the year of their last update.

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005

News & Analysis

Latest news and insights on clinical trials and medical research.

Browse All News →
MedTrace Logo MedTrace
About Privacy Policy Terms of Service Medical Disclaimer

© 2026 MedTrace.
Open-access medical & pharmaceutical data intelligence.